Compare TYL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYL | TEVA |
|---|---|---|
| Founded | 1966 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | TYL | TEVA |
|---|---|---|
| Price | $468.39 | $28.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $666.78 | $27.00 |
| AVG Volume (30 Days) | 378.0K | ★ 11.4M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.32 | N/A |
| EPS | ★ 7.19 | 0.62 |
| Revenue | $2,298,292,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $10.96 | $4.74 |
| Revenue Next Year | $8.90 | $0.48 |
| P/E Ratio | $65.26 | ★ $46.12 |
| Revenue Growth | ★ 10.62 | 0.02 |
| 52 Week Low | $450.00 | $12.47 |
| 52 Week High | $661.31 | $28.68 |
| Indicator | TYL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 80.93 |
| Support Level | $460.60 | $24.01 |
| Resistance Level | $469.29 | $26.96 |
| Average True Range (ATR) | 9.94 | 0.68 |
| MACD | 2.01 | 0.19 |
| Stochastic Oscillator | 57.34 | 94.65 |
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.